EcoDrugPlus

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSOMYG00000022278
Gene Symbol: PDE5AB
1 Cross references
217 Possible Orthologues:

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSOMYG00000007783
Gene Symbol: PDE5AB
1 Cross references
217 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSOMYG00000003923
Gene Symbol: PDE7A
1 Cross references
220 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSOMYG00000036242
Gene Symbol: PDE7A
1 Cross references
220 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSOMYG00000034482
Gene Symbol: PDE7A
1 Cross references
174 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSOMYG00000040279
Gene Symbol: PDE7A
1 Cross references
169 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSOMYG00000000044
Gene Symbol: PDE9A
1 Cross references
179 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSOMYG00000047715
Gene Symbol: PDE9A
1 Cross references
179 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSOMYG00000009118
Gene Symbol: PIK3R1
2 Cross references
196 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSOMYG00000033359
Gene Symbol: PIK3R1
1 Cross references
196 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSOMYG00000000711
Gene Symbol: PIK3R2
1 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSOMYG00000025086
Gene Symbol: PIK3R3
1 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).